A Study of LY3437943 in Participants With Type 2 Diabetes

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Dulaglutide

Criteria

Inclusion Criteria:

• Have Type 2 Diabetes (T2D)

• Have an HbA1c value at screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or with a stable dose of metformin (either immediate release or extended release, 1000 milligram (mg)/day and not more than the locally approved dose) for at least 3 months prior to screening.

Exclusion Criteria:

• Have type 1 diabetes mellitus (T1DM)

• Have ketoacidosis

• Have retinopathy, maculopathy

• Have history of pancreatitis

• Have obesity induced by other endocrine disorders

• Have uncontrolled hypertension

• Have acute or chronic hepatitis

• Have chronic kidney disease

• Have an autoimmune abnormality for example, lupus or rheumatoid arthritis

• Have an active or untreated malignancy